Skip to main content
. Author manuscript; available in PMC: 2010 Feb 12.
Published in final edited form as: Circ Res. 2009 Apr 2;104(9):1095–1102. doi: 10.1161/CIRCRESAHA.108.192138

Figure 6.

Figure 6

Wound closure, facilitated by unmodified CD133+ CCM, is retarded as compared to vehicle, when Wnt antagonist sFRP-1 is added (A). Treatment of wounds with sFRP-1 in the absence of CD133+ CCM did not modulate wound closure (A). Likewise, capillarization of wounds was supported by CD133+ CCM only in the absence of sFRP-1 (B) (n=7 per group). *P<0.05, **P<0.01, ***P<0.005 vs NCCM, +++P<0.005 vs CD133+ CCM.